Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors ...Middle East

SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other...

Hence then, the article about innovent announces the first patient dosed in the phase 1 study of ibi321 anti pd 1 tigit bispecific antibody in patients with advanced malignant tumors was published today ( Monday 26/07/2021 - 04:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors )

Also on site :

• The ‘rules-based order’ has failed in its mission – helping the West do whatever it wants
• Armed police close Lewes Road
• Intrigue, Power Plays and Rivalries: Inside the Rise of Mojtaba Khamenei